N/A N=22 Pediatric Emergency Department Smartphone Otoscope Study (PED-Oto)
Acute Otitis Media · Acute Otitis Externa
Primary: Number of Antibiotic Prescriptions — 140; 115; 6; 7 Emergency department encounters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=447 Multidisciplinary Support Program in Chronic Hepatitis C
Hepatitis C, Chronic
Primary: Adherence to Treatment — 116; 155; 124 participants
Phase 4 N=19 Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic Constipation
Chronic Idiopathic Constipation
Primary: Gastric Emptying — 0.27; 0.384; 0.04; 0.051 percent meal retention — p=0.003
N/A N=24 Probiotics in Infants With Gastroschisis
Gastroschisis
Primary: Composition of the Fecal Microbiota — 42; 12; 1.1; 14 percentage of total bacteria — p=<0.01
N/A N=11 Smoking Treatment and Exercise Program for Underserved Populations (STEP UP)
Smoking
Primary: Number of Participants Who Self-report Prolonged Abstinence From Smoking — 3 Participants
Phase 3 N=1,810 A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 24 — 0.142; -0.029 Liters (L) — p=<0.001
Phase 3 N=612 A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin
Chronic Kidney Disease · Chronic Renal Failure
Primary: Mean Weekly Hemoglobin Level From Week 21 to Week 24 — 10.17; 10.28 g/dL
N/A N=648 Evaluating Advantages of Prevena After Hip and Knee Arthroplasty
Infection of Total Hip Joint Prosthesis
Primary: Number of Participants With Hospital Readmissions — 15; 3 Participants
N/A N=24 Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure
Atrial Fibrillation · Heart Failure
Primary: Correlation of Heart Failure Risk Score (HFRS) With Heart Failure Events — 5; 2; 2; 7 participants
Phase 2 N=32 A Study of Single and Multiple Doses of Oral Insulin or Placebo in Subjects With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Change in Glucose Levels Between Pre-treatment and End of Treatment as Measured by 24-hour Continuous Glucose Monitoring (CGM) — -4.94; -10.00; -1.21; -11.42 mg/dL…
Phase 4 N=32 Tranexamic Acid in Adolescents With Heavy Menstrual Bleeding
Heavy Menstrual Bleeding
Primary: Change From Baseline Menses for Participant Perceived Blood Loss — 3; 1.9 score on a scale
Phase 3 N=100 Study of Ceftolozane/Tazobactam (MK-7625A) in Combination With Metronidazole in Japanese Participants With Complicated Intra-abdominal Infection (MK-7625A-013)
Intra-abdominal Infection · Complicated Intra-abdominal Infection
Primary: Percentage of Participants With Clinical Response (Clinical Cure, Clinical Failure, or Indeterminate) at Test of Cure (TOC) — 92.0; 8.0; 0.0 Percentage of Participants
Phase 2 N=19 Gabapentin Treatment of Benzodiazepine Abuse in Methadone Maintenance Patients
Benzodiazepine Dependence · Opioid Dependence
Primary: Mean Reduction Change in Benzodiazepine Use Per Day Based on Time Line Follow Back — 4.0; 2.3 milligrams/day
Phase 4 N=20 Nexplanon and Combined Oral Contraceptive (COC) Combined Use Study
Contraception
Primary: Number of Participants Evaluating ENG as Acceptable: Acceptability (Measurement: Questionnaire) — 9; 8 Participants
Phase 4 N=58 How Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used?
Glaucoma
Primary: Change in Tear Break up Time (TBUT) — -0.86; -0.59; -2.00; 0.27 seconds — p=0.005